mRNA Vaccine Production QC: Validated Inorganic Pyrophosphatase ELISA Kit

In mRNA therapeutics production, inorganic pyrophosphatase (PPase) hydrolyzes inhibitory pyrophosphate (PPi) – a byproduct of in vitro transcription. PPi accumulation suppresses RNA polymerase activity, reducing RNA yield (>30% efficiency loss). PPase catalyzes:

P₂O₇^4-+H₂O+PPase→2HPO₄^2-

This exergonic reaction (ΔG = –19.2 kJ/mol) eliminates transcriptional inhibition and provides thermodynamic driving force for RNA elongation, enhancing productivity. At commercial scale, PPase prevents PPi-induced reaction stalling in large-volume systems, making it indispensable for industrial mRNA manufacturing. The enzyme's function directly governs production capacity and process robustness.

In mRNA vaccine production, inorganic pyrophosphatase (PPase) acts as a process-related impurity. Residual PPase poses immunogenicity risks and compromises product purity, requiring stringent quantitation. A validated double-antibody sandwich ELISA (DEIA-HP3807) enables highly specific detection of PPase residues in mRNA drug substances. This method ensures sensitive monitoring of process-derived impurities during manufacturing, with demonstrated robustness against matrix interference. Implementation supports critical quality control and regulatory compliance.

Data Display:

Figure 1. Example of a standard curve for DEIA-HP3807